- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 5 Feb 2022 - 11 Feb 2022
Pharmacology/Drug Development
2021
Front Immunol
12
Non-operative management of trapeziometacarpal osteoarthritis (TMOA) demonstrates only short-term symptomatic alleviation, and no approved disease modifying drugs exist to treat this condition. A key issue in these patients is that radiographic disease severity can be discordant with patient reported pain, illustrating the need to identify molecular mediators of disease. This study characterizes the biochemical profile of TMOA patients to elucidate molecular mechanisms driving TMOA progression.